678 related articles for article (PubMed ID: 24854434)
21. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.
Hess EJ; Moody KA; Geffrey AL; Pollack SF; Skirvin LA; Bruno PL; Paolini JL; Thiele EA
Epilepsia; 2016 Oct; 57(10):1617-1624. PubMed ID: 27696387
[TBL] [Abstract][Full Text] [Related]
22. The anticonvulsant effects of cannabidiol in experimental models of epileptic seizures: From behavior and mechanisms to clinical insights.
Lazarini-Lopes W; Do Val-da Silva RA; da Silva-Júnior RMP; Leite JP; Garcia-Cairasco N
Neurosci Biobehav Rev; 2020 Apr; 111():166-182. PubMed ID: 31954723
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
Franco V; Perucca E
Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958
[TBL] [Abstract][Full Text] [Related]
24. Cannabinoids in treatment-resistant epilepsy: A review.
O'Connell BK; Gloss D; Devinsky O
Epilepsy Behav; 2017 May; 70(Pt B):341-348. PubMed ID: 28188044
[TBL] [Abstract][Full Text] [Related]
25. Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research.
Franco V; Bialer M; Perucca E
Neuropharmacology; 2021 Mar; 185():108442. PubMed ID: 33347884
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
Rosenberg EC; Patra PH; Whalley BJ
Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
[TBL] [Abstract][Full Text] [Related]
27. Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report.
Saade D; Joshi C
Pediatr Neurol; 2015 May; 52(5):544-7. PubMed ID: 25882081
[TBL] [Abstract][Full Text] [Related]
28. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
[TBL] [Abstract][Full Text] [Related]
29. Cannabis for paediatric epilepsy: challenges and conundrums.
Chen KA; Farrar MA; Cardamone M; Lawson JA
Med J Aust; 2018 Feb; 208(3):132-136. PubMed ID: 29438649
[TBL] [Abstract][Full Text] [Related]
30. Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery.
Del Pozo A; Barker-Haliski M
Exp Neurol; 2023 Feb; 360():114288. PubMed ID: 36471511
[TBL] [Abstract][Full Text] [Related]
31. Biochemical aspects and therapeutic mechanisms of cannabidiol in epilepsy.
Boleti APA; Frihling BEF; E Silva PS; Cardoso PHO; de Moraes LFRN; Rodrigues TAA; Biembengute MEF; Koolen HHF; Migliolo L
Neurosci Biobehav Rev; 2022 Jan; 132():1214-1228. PubMed ID: 33031814
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis.
Lattanzi S; Brigo F; Cagnetti C; Trinka E; Silvestrini M
CNS Drugs; 2018 Oct; 32(10):905-916. PubMed ID: 30132269
[TBL] [Abstract][Full Text] [Related]
33. Cannabidiol in canine epilepsy.
Potschka H; Bhatti SFM; Tipold A; McGrath S
Vet J; 2022 Dec; 290():105913. PubMed ID: 36209995
[TBL] [Abstract][Full Text] [Related]
34. Cannabidiol for treatment of refractory childhood epilepsies: Experience from a single tertiary epilepsy center in Slovenia.
Neubauer D; Perković Benedik M; Osredkar D
Epilepsy Behav; 2018 Apr; 81():79-85. PubMed ID: 29526578
[TBL] [Abstract][Full Text] [Related]
35. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.
Porter BE; Jacobson C
Epilepsy Behav; 2013 Dec; 29(3):574-7. PubMed ID: 24237632
[TBL] [Abstract][Full Text] [Related]
36. Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials.
Dos Santos RG; Guimarães FS; Crippa JAS; Hallak JEC; Rossi GN; Rocha JM; Zuardi AW
Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):517-526. PubMed ID: 32271618
[TBL] [Abstract][Full Text] [Related]
37. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy.
McGrath S; Bartner LR; Rao S; Packer RA; Gustafson DL
J Am Vet Med Assoc; 2019 Jun; 254(11):1301-1308. PubMed ID: 31067185
[TBL] [Abstract][Full Text] [Related]
38. Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.
Anderson LL; Heblinski M; Absalom NL; Hawkins NA; Bowen MT; Benson MJ; Zhang F; Bahceci D; Doohan PT; Chebib M; McGregor IS; Kearney JA; Arnold JC
Br J Pharmacol; 2021 Dec; 178(24):4826-4841. PubMed ID: 34384142
[TBL] [Abstract][Full Text] [Related]
39. Development of cannabidiol as a treatment for severe childhood epilepsies.
Williams CM; Stephens GJ
Br J Pharmacol; 2020 Dec; 177(24):5509-5517. PubMed ID: 32986848
[TBL] [Abstract][Full Text] [Related]
40. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures.
Jones NA; Glyn SE; Akiyama S; Hill TD; Hill AJ; Weston SE; Burnett MD; Yamasaki Y; Stephens GJ; Whalley BJ; Williams CM
Seizure; 2012 Jun; 21(5):344-52. PubMed ID: 22520455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
